GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSK - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $1.06 per share and revenue of $7.52 billion for the quarter. GSK has set its FY 2025 guidance at 2.090-2.130 EPS.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Up 1.6 %

NYSE:GSK traded up $0.58 on Monday, hitting $38.01. The stock had a trading volume of 1,459,533 shares, compared to its average volume of 4,700,507. The firm's fifty day simple moving average is $37.50 and its two-hundred day simple moving average is $36.00. The stock has a market cap of $78.43 billion, a P/E ratio of 23.90, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. GSK has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.14%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. GSK's payout ratio is presently 100.63%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GSK stock. Brighton Jones LLC bought a new stake in shares of GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,604 shares of the pharmaceutical company's stock, valued at approximately $528,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GSK shares. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Finally, BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Eight research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.